NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
(Total Views: 263)
Posted On: 08/30/2018 5:37:04 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Reports Additional Encouraging Results from DehydraTECH™ Nicotine Study
Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) this morning announced further results from its recently completed second-generation study in 40 rats in addition to the partial results released earlier this month. The in vivo study evaluated the ability of the company’s DehydraTECH™ technology to deliver nicotine as quickly as 2 minutes after oral administration. Lexaria’s technology delivered 90.2% more nicotine over the first 10 minutes of the study than the concentration-matched control formulation by the 10-minute mark. To better commercialize opportunities within the nicotine sector, the company has also completed the formation of a wholly-owned subsidiary, Lexaria Nicotine Corp. “Lexaria’s DehydraTECH™ delivery technology continues to demonstrate its superior effectiveness in delivering nicotine without the need for combustion or the need for inhalation whatsoever,” Lexaria Bioscience Corp CEO Chris Bunka stated in the news release. “Crossing the blood brain barrier is a significant achievement all on its own and this data confirms the outcome of our earlier first-generation test.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) this morning announced further results from its recently completed second-generation study in 40 rats in addition to the partial results released earlier this month. The in vivo study evaluated the ability of the company’s DehydraTECH™ technology to deliver nicotine as quickly as 2 minutes after oral administration. Lexaria’s technology delivered 90.2% more nicotine over the first 10 minutes of the study than the concentration-matched control formulation by the 10-minute mark. To better commercialize opportunities within the nicotine sector, the company has also completed the formation of a wholly-owned subsidiary, Lexaria Nicotine Corp. “Lexaria’s DehydraTECH™ delivery technology continues to demonstrate its superior effectiveness in delivering nicotine without the need for combustion or the need for inhalation whatsoever,” Lexaria Bioscience Corp CEO Chris Bunka stated in the news release. “Crossing the blood brain barrier is a significant achievement all on its own and this data confirms the outcome of our earlier first-generation test.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)